{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:59:37Z","timestamp":1760547577372},"reference-count":11,"publisher":"Elsevier BV","issue":"8451","license":[{"start":{"date-parts":[[1985,8,1]],"date-time":"1985-08-01T00:00:00Z","timestamp":491702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[1985,8]]},"DOI":"10.1016\/s0140-6736(85)92543-7","type":"journal-article","created":{"date-parts":[[2003,9,22]],"date-time":"2003-09-22T19:07:43Z","timestamp":1064257663000},"page":"396","source":"Crossref","is-referenced-by-count":9,"title":["FAILURE (AND DANGER) OF MITOZANTRONE IN AIDS-RELATED KAPOSI'S SARCOMA"],"prefix":"10.1016","volume":"326","author":[{"given":"Lawrence","family":"Kaplan","sequence":"first","affiliation":[]},{"given":"PaulA.","family":"Volberding","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(85)92543-7_BIB1","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1200\/JCO.1984.2.10.1115","article-title":"Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine","volume":"2","author":"Laubenstein","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(85)92543-7_BIB2","series-title":"Vinblastine therapy of AIDS-related Kaposi's sarcoma (KS) Proceedings of International Conference on Acquired Immunodeficiency Syndrome (AIDS)","author":"Volberding","year":"1985"},{"key":"10.1016\/S0140-6736(85)92543-7_BIB3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-102-2-200","article-title":"Treatment of Kaposi's sarcoma and thrombocytopenia with vioblastine in patients with the acquired immunodeficiency syndrome","volume":"102","author":"Mintzer","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0140-6736(85)92543-7_BIB4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.7326\/0003-4819-100-5-671","article-title":"Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome","volume":"100","author":"Groopman","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0140-6736(85)92543-7_BIB5","first-page":"115","article-title":"Mitoxantrone hydrochloride in hematologic malignancies Southwest Oncology Group, phase II studies","author":"Coltman","year":"1983"},{"key":"10.1016\/S0140-6736(85)92543-7_BIB6","doi-asserted-by":"crossref","first-page":"694","DOI":"10.7326\/0003-4819-95-6-694","article-title":"Dihydroxyanthracenedione A promising new drug in the treatment of metasiatic breast cancer","volume":"95","author":"Yap","year":"1981","journal-title":"Ann Intern Med"},{"key":"10.1016\/S0140-6736(85)92543-7_BIB7","first-page":"1133","article-title":"Mitoxantrone: Modest activity in a phase II trial in advanced prostate cancer","volume":"67","author":"Osborne","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/S0140-6736(85)92543-7_BIB8","first-page":"202","article-title":"A phase II study of mitozantrone (NSC 301 739) in patients with primary liver cancer (PLC)","volume":"C-789","author":"Van Echo","year":"1984","journal-title":"Proc ASCO"},{"key":"10.1016\/S0140-6736(85)92543-7_BIB9","unstructured":"Investigators drug brochure Mitozantrone, overall study of safety and efficacy American Cyanamid Company"},{"key":"10.1016\/S0140-6736(85)92543-7_BIB10","first-page":"40","article-title":"Evaluation of mitozantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy","volume":"C-156","author":"Benjamin","year":"1984","journal-title":"Proc ASCO"},{"key":"10.1016\/S0140-6736(85)92543-7_BIB11","first-page":"1516","article-title":"Phase I clinical investigation of 1,4-dihydroxy-5,8-61's ((z-(z-hydroxyethyl) amino)-ethyl)amino) 9,10-anthracenedione dihydrochloride (NSC-301739) a new anthracenedione","volume":"40","author":"Von Hoff","year":"1980","journal-title":"Cancer Res"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673685925437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673685925437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T13:27:01Z","timestamp":1550928421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673685925437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,8]]},"references-count":11,"journal-issue":{"issue":"8451","published-print":{"date-parts":[[1985,8]]}},"alternative-id":["S0140673685925437"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(85)92543-7","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[1985,8]]}}}